JP2014527084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014527084A5 JP2014527084A5 JP2014530899A JP2014530899A JP2014527084A5 JP 2014527084 A5 JP2014527084 A5 JP 2014527084A5 JP 2014530899 A JP2014530899 A JP 2014530899A JP 2014530899 A JP2014530899 A JP 2014530899A JP 2014527084 A5 JP2014527084 A5 JP 2014527084A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- polypeptide
- mammal
- item
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 53
- 229920001184 polypeptide Polymers 0.000 claims description 52
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 52
- 229960005486 vaccine Drugs 0.000 claims description 39
- 241000124008 Mammalia Species 0.000 claims description 35
- 241000589291 Acinetobacter Species 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 241000222122 Candida albicans Species 0.000 claims description 12
- 230000002163 immunogen Effects 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 206010007134 Candida infections Diseases 0.000 claims description 11
- 201000003984 candidiasis Diseases 0.000 claims description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000002255 vaccination Methods 0.000 claims description 8
- 238000007918 intramuscular administration Methods 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 2
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 2
- 241000237536 Mytilus edulis Species 0.000 claims description 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 2
- 238000007792 addition Methods 0.000 claims description 2
- 230000027455 binding Effects 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 108060003552 hemocyanin Proteins 0.000 claims description 2
- 235000020638 mussel Nutrition 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 229960000814 tetanus toxoid Drugs 0.000 claims description 2
- 239000000277 virosome Substances 0.000 claims description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 claims 1
- 229940124551 recombinant vaccine Drugs 0.000 claims 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 47
- 239000012634 fragment Substances 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 238000000034 method Methods 0.000 description 20
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 12
- 101710116435 Outer membrane protein Proteins 0.000 description 12
- 101100208518 Arabidopsis thaliana UGT71B2 gene Proteins 0.000 description 11
- 101150102882 HYR1 gene Proteins 0.000 description 11
- 239000002243 precursor Substances 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- 230000032823 cell division Effects 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 102000004895 Lipoproteins Human genes 0.000 description 6
- 108090001030 Lipoproteins Proteins 0.000 description 6
- 102000018897 Membrane Fusion Proteins Human genes 0.000 description 6
- 108010027796 Membrane Fusion Proteins Proteins 0.000 description 6
- 229910052742 iron Inorganic materials 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 208000034950 Acinetobacter Infections Diseases 0.000 description 5
- 108700001249 Cell division protein FtsZ Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 108010089727 siderophore receptors Proteins 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 4
- 102000017033 Porins Human genes 0.000 description 4
- 108010013381 Porins Proteins 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 3
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102000010562 Peptide Elongation Factor G Human genes 0.000 description 3
- 108010077742 Peptide Elongation Factor G Proteins 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 101900334855 Acinetobacter baumannii Elongation factor G Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 108700033568 Acinetobacter baumannii AdeA Proteins 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 101710117971 Peptide Y Proteins 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161534734P | 2011-09-14 | 2011-09-14 | |
| US61/534,734 | 2011-09-14 | ||
| US201161564201P | 2011-11-28 | 2011-11-28 | |
| US61/564,201 | 2011-11-28 | ||
| PCT/US2012/055604 WO2013040478A2 (en) | 2011-09-14 | 2012-09-14 | Hyr1-derived compositions and methods of treatment using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014527084A JP2014527084A (ja) | 2014-10-09 |
| JP2014527084A5 true JP2014527084A5 (https=) | 2015-11-05 |
Family
ID=47884005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014530899A Pending JP2014527084A (ja) | 2011-09-14 | 2012-09-14 | Ｈｙｒ１由来組成物およびそれを使用する処置方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10160790B2 (https=) |
| EP (1) | EP2755668A4 (https=) |
| JP (1) | JP2014527084A (https=) |
| CN (1) | CN103998049A (https=) |
| AU (1) | AU2012308281A1 (https=) |
| BR (1) | BR112014005773A2 (https=) |
| CA (1) | CA2848403A1 (https=) |
| EA (1) | EA025831B1 (https=) |
| GE (2) | GEP20197052B (https=) |
| UA (1) | UA115305C2 (https=) |
| WO (1) | WO2013040478A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070077256A1 (en) | 1999-11-19 | 2007-04-05 | Los Angeles Biomedical Research Institute | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents |
| US10130691B2 (en) | 2013-03-15 | 2018-11-20 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Compositions and methods for treating fungal and bacterial pathogens |
| EP2942389A1 (en) * | 2014-05-05 | 2015-11-11 | Servicio Andaluz De Salud | Vaccine against Acinetobacter baumannii based on lipopolysaccharide-deficient cellular components |
| GB201503812D0 (en) * | 2015-03-06 | 2015-04-22 | Univ Aberdeen | Antibody molecules and uses thereof |
| CN108472372B (zh) * | 2015-07-13 | 2022-05-17 | 海港医学中心洛杉矶生物医学研究所 | 结合不动杆菌的抗体结合剂及其用途 |
| EP3426287A4 (en) | 2016-03-09 | 2020-03-11 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | Methods and kits for use in preventing and treating vulvovaginal candidiasis |
| GB201902769D0 (en) * | 2019-03-01 | 2019-04-17 | Univ Court Of The Univ Of Aberdeen | Antibody molcules and uses thereof |
| US20220354935A1 (en) * | 2021-04-21 | 2022-11-10 | Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center | Vaccination against fungal epitopes to prevent inflammatory bowel diseases |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100150942A1 (en) * | 2008-12-03 | 2010-06-17 | Cantor Thomas L | Affinity purified human polyclonal antibodies and methods of making and using them |
| WO2011003085A1 (en) | 2009-07-03 | 2011-01-06 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Hyr1 as a target for active and passive immunization against candida |
-
2012
- 2012-09-14 BR BR112014005773-7A patent/BR112014005773A2/pt not_active IP Right Cessation
- 2012-09-14 GE GEAP201213226A patent/GEP20197052B/en unknown
- 2012-09-14 EP EP12832321.9A patent/EP2755668A4/en not_active Withdrawn
- 2012-09-14 JP JP2014530899A patent/JP2014527084A/ja active Pending
- 2012-09-14 US US14/344,838 patent/US10160790B2/en active Active
- 2012-09-14 UA UAA201310982A patent/UA115305C2/uk unknown
- 2012-09-14 GE GEAP201913226A patent/GEAP201913226A/en unknown
- 2012-09-14 AU AU2012308281A patent/AU2012308281A1/en not_active Abandoned
- 2012-09-14 CA CA2848403A patent/CA2848403A1/en not_active Abandoned
- 2012-09-14 WO PCT/US2012/055604 patent/WO2013040478A2/en not_active Ceased
- 2012-09-14 CN CN201280056018.2A patent/CN103998049A/zh active Pending
- 2012-09-14 EA EA201391199A patent/EA025831B1/ru not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014527084A5 (https=) | ||
| US9181308B2 (en) | Methods and compositions employing immunogenic fusion proteins | |
| JP7744353B2 (ja) | プロピオニバクテリウム・アクネスの予防的かつ治療的な免疫処置 | |
| JP5792630B2 (ja) | Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用 | |
| AU2018290298B2 (en) | Immunogenic compositions | |
| US9241987B2 (en) | Methods and compositions related to immunogenic fibrils | |
| Bazan et al. | Phage display—A powerful technique for immunotherapy: 2. Vaccine delivery | |
| EP3818989A1 (en) | Peptides and oligonucleotides for a sars-cov-2 vaccine | |
| CA2730686A1 (en) | Anti-amyloid immunogenic compositions, methods and uses | |
| AU2012308281A1 (en) | Hyr1-derived compositions and methods of treatment using same | |
| CN102471770A (zh) | 抗原肽及其用途 | |
| US20120251565A1 (en) | Compositions and methods for preventing or treating burkholderia infection | |
| CA2760239A1 (en) | Polypeptide derived from enterococcus and its use for vaccination | |
| EP3833387A1 (en) | Compositions and methods for preventing and treating virus infection | |
| WO2012163533A1 (en) | T cell epitope of candida albicans | |
| EP4138901A1 (en) | Compositions and methods for inducing immune responses against class i fusion protein viruses | |
| WO2023192997A2 (en) | Immunogenic compositions for b-cell recall response to a polysaccharide antigen | |
| CN100368436C (zh) | 人绒毛膜促性腺激素重组多表位嵌合肽cp22抗原的分子设计及其制备方法 | |
| US10556002B2 (en) | Dual anthrax-plague vaccines that can protect against two tier-1 bioterror pathogens, Bacillus anthracis and Yersinia pestis | |
| WO2025080765A1 (en) | Methods to deliver exogenous protein/peptide cargo to cell cytosol and uses thereof | |
| HK40106055A (en) | Immunogenic compositions | |
| WO2023081861A9 (en) | Enhanced expression via autotransporters | |
| EP4045672A1 (en) | Compositions and methods for producing enhanced immune responses and rapid antibody production | |
| WO2021122551A1 (en) | S. aureus antigens and compositions thereof | |
| HK40021266B (en) | Immunogenic compositions |